ClinicalTrials.gg

Program

VC005

A development code. Also written as “VC005 tablets”, “VC005 Tablets” and “VC005 and verapamil”.

Its studies are mostly in Dermatitis, Atopic · Alopecia Areata · Vitiligo · Spondylitis, Ankylosing · Inflammatory Bowel Diseases, led by Jiangsu vcare pharmaceutical technology.

Furthest: phase 3, since Dec 5, 202421 company-led studies, 9 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu vcare pharmaceutical technology219 open or runningphase 3since Dec 5, 2024Oct 25, 2021Nov 30, 2026phase 1 · NCT07796191

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Oct 25, 2021.

  1. Aug 10, 2023Phase 2 study in Moderate to Severe Atopic DermatitisNCT05997927 · 149 enrolled · China
  2. Aug 18, 2023Phase 1 study in Dermatitis, AtopicNCT06009094 · 80 enrolled · China
  3. Dec 5, 2024Phase 3 study in Moderate to Severe Atopic DermatitisNCT06723080 · 480 planned · China
  4. Mar 18, 2025Phase 2 study in Dermatitis, AtopicNCT06891040 · 118 enrolled · China
  5. May 6, 2025Phase 1 study in Dermatitis, AtopicNCT06974292 · 6 enrolled · China
  6. Sep 8, 2025Phase 3 study in Active Ankylosing SpondylitisNCT07172360 · 420 planned · China
  7. Sep 8, 2025Phase 2 study in Non-segmental VitiligoNCT07172347 · 120 planned · China
  8. Dec 29, 2025Phase 1 study in Dermatitis, AtopicNCT07329101 · 11 enrolled · China
  9. Apr 10, 20263 phase 1 studiesNCT07533851, NCT07551570, NCT07551557
  10. May 12, 2026Phase 3 study in Dermatitis, AtopicNCT07592585 · 360 planned · China
  11. May 14, 2026Phase 2 study in Dermatitis, AtopicNCT07598383 · 120 planned · China
  12. Aug 3, 2026Phase 2 study in Alopecia AreataNCT07749716 · 120 planned · China
  13. Aug 9, 20262 phase 1 studiesNCT07762443, NCT07796191
  14. Sep 15, 2026Phase 2 study in Non-Segmental VitiligoNCT07828639 · 10 planned · China

Ahead

  1. Nov 30, 2026Primary completion: phase 1 study in Healthy Adult ParticipantsNCT07796191
  2. Feb 22, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07598383
  3. May 30, 2027Primary completion: phase 2 study in Non-Segmental VitiligoNCT07828639
  4. Aug 30, 2027Primary completion: phase 3 study in Active Ankylosing SpondylitisNCT07172360

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07828639Non-Segmental Vitiligo · China2Not yet recruitingMay 30, 202710
NCT07796191Healthy Adult Participants · China1Not yet recruitingNov 30, 202684
NCT07762443Alopecia Areata · China1RecruitingDec 30, 202724
NCT07749716Alopecia Areata · China2RecruitingDec 30, 2028120
NCT07598383Dermatitis, Atopic · China2RecruitingFeb 22, 2027120
NCT07592585Dermatitis, Atopic · China3RecruitingMay 30, 2028360
NCT07551570Renal Insufficiency · China1CompletedAug 2, 202632
NCT07551557Hepatic Impairment and Healthy Female · China1CompletedAug 2, 202624
NCT07533851Dermatitis, Atopic · China1CompletedApr 30, 202631
NCT07329101Dermatitis, Atopic · China1CompletedFeb 6, 202611
NCT07172360Active Ankylosing Spondylitis · China3RecruitingAug 30, 2027420
NCT07172347Non-segmental Vitiligo · China2RecruitingAug 30, 2027120
NCT06974292Dermatitis, Atopic · China1CompletedJun 3, 20256
NCT06891040Dermatitis, Atopic · China2CompletedOct 31, 2025118
NCT06723080Moderate to Severe Atopic Dermatitis · China3RecruitingAug 30, 2027480
NCT06009094Dermatitis, Atopic · China1CompletedMay 23, 202480
NCT05997927Moderate to Severe Atopic Dermatitis · China2CompletedJul 9, 2024149
NCT05874622Arthritis, Rheumatoid · China1CompletedOct 18, 202330
NCT05814939Active Ankylosing Spondylitis · China2CompletedMay 11, 2024180
NCT05354752Inflammatory Bowel Diseases · China1CompletedNov 2, 202260
NCT05138770Inflammatory Bowel Diseases · China1CompletedAug 26, 202278

How it is read

Names in the registry

  • “VC005 tablets”, 9 entries
  • “VC005 Tablets”, 5 entries
  • “VC005”, 3 entries
  • “VC005 and verapamil”, 1 entry
  • “VC005 and probenecid”, 1 entry

Codes read as this program: VC005.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
VC005 (Jiangsu vcare pharmaceutical technology): development program | ClinicalTrials.gg